BioCentury
ARTICLE | Company News

Synpromics, UCL partner to develop tissue-specific promoters

January 26, 2018 9:07 PM UTC

Synpromics Ltd. (Edinburgh, U.K.) partnered with the Great Ormond Street Institute of Child Health at University College London (London, U.K.) to discover and develop gene therapies for pathologies affecting the hematopoietic system.

The partners will develop synthetic tissue-specific promoters for use in specialized immune cells, including lymphoid, myeloid and microglia cells. Synpromics will design and build libraries of promoter candidates which UCL will screen in its in vitro cell models and in vivo disease models. Synpromics and the university hope to apply the promoters to a gene-modified cell therapy, especially one in which microglia or other myeloid cells could be used to deliver a therapeutic protein. Synpromics said the collaborators will initially target chronic granulomatous disorder...